Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Fulvio,Massaro

第一单位： Hematology, AUSL/IRCCS Reggio Emilia, Reggio Emilia, Italy.

作者： Fulvio,Massaro ^[1] ; Yana,Stepanishyna ^[2] ; Martina,Manni ^[3] ; Stefano,Luminari ^[4] ; Sara,Galimberti ^[1] ; Luigi,Marcheselli ^[4] ; Carlo,Visco ^[5] ; Cristina,Tecchio ^[6] ; Caterina,Stelitano ^[7] ; Francesco,Angrilli ^[7] ; Mario,Petrini ^[8] ; Francesco,Merli ^[9] ; Massimo,Federico ^[5]

作者单位： Hematology, AUSL/IRCCS Reggio Emilia, Reggio Emilia, Italy. ^[1] PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Italy. ^[2] Research Department of Hemoblastosis Chemotherapy, National Cancer Institute, Kyiv, Ukraine. ^[3] CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy. ^[4] Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy. ^[5] Fondazione Italiana Linfomi (FIL) Onlus, Modena, Italy. ^[6] Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy. ^[7] Division of Haematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy. ^[8] Ematologia Ospedale Civile dello Spirito Santo, Pescara, Italy. ^[9]

关键词 Hyper-CVAD-AM long-term analysis mantle cell lymphoma second malignancies survival